Last reviewed · How we verify
acetated Ringers
Acetated Ringers, marketed by University Hospital, Linkoeping, is an established solution in the healthcare sector with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and long-standing use in clinical settings. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | acetated Ringers |
|---|---|
| Also known as | Ringer's acetate, ringer acetate, acetate Ringer´s |
| Sponsor | University Hospital, Linkoeping |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fluid Challenge and Plasma Volume, During Surgery (PHASE4)
- Fluid Management in Patients Undergoing Cardiac Surgery (PHASE4)
- Volume Kinetics for Starch Solution and Acetated Ringers (NA)
- "The Effect of Reduced Fluid Load After Cardiac Surgery"
- Kinetic Method to Detect Dehydration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- acetated Ringers CI brief — competitive landscape report
- acetated Ringers updates RSS · CI watch RSS
- University Hospital, Linkoeping portfolio CI